Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 18
Submit an article Journal homepage
616
Views
41
CrossRef citations to date
0
Altmetric
Review

Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease

Clive Kelly Queen Elizabeth Hospital Foundation Trust, Department of Rheumatological Medicine, Sheriff Hill, Gateshead NE9 6SX, UK +44 191 445 2193; [email protected]
, MBBS FRCP MD &
Vadivelu Saravanan Queen Elizabeth Hospital Foundation Trust, Department of Rheumatological Medicine, Sheriff Hill, Gateshead NE9 6SX, UK +44 191 445 2193; [email protected]
, MBBS MRCP
Pages 3221-3230 | Published online: 28 Nov 2008

Bibliography

  • Young A, Koduri G, Batley M, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatol (Oxf) 2007;46(2):350-7
  • Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003;62(8):722-7
  • Turesson C, O'Fallon WM, Crowson CS, et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002;29(1):62-7
  • McDonagh J, Greaves M, Wright AR, et al. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br J Rheumatol 1994;33:118-22
  • Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology 2002;41:676-9
  • Rajasekaran A, Shovlin D, Saravanan V, et al. Interstitial lung disease in patients with rheumatoid arthritis; comparison with cryptogenic fibrosing alveolitis over five years. J Rheumatol 2006;33:1250-4
  • Wells AU, Hansell DM, Corrin B, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992;47:738-42
  • Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography and pulmonary function tests. Thorax 2001;56:622-7
  • Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007;175(7):705-11
  • Turesson C, Matteson EL, Vuk-Pavlovic Z, et al. Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum 2005;52:73-9
  • Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004;44:585-96
  • Lee HK, Lim DS, Yoo B, et al. Histologic pattern and clinical features of rheumatoid arthritis associated interstitial lung disease. Chest 2005;127:2019-27
  • Haykawa H, Sato A, Imokawa S, et al. Bronchiolar disease in rheumatoid arthritis. Am J Respir Crit Care Med 1996;154:1531-6
  • Dawson JK, Fewins HE, Desmond J, et al. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis 2002;616:517-21
  • Weyand CM, Schmidt D, Wagner U, et al. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum 1998;41:817-22
  • Vergnenegre A, Pugnere N, Antonimi NT, et al. Airways obstruction and rheumatoid arthritis. Eur Respir J 1997;10:1072-8
  • Turesson C, Jacobsson LTH. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004;33:65-72
  • Grutters JC, du Bois RM. Genetics of fibrosing lung diseases. Eur Respir J 2005;25(5):915-27
  • Sugiyama Y, Ohmo S, Kano S. Diffuse panbronchiolitis and rheumatoid arthritis: a possible correlation with HLA-B54. Intern Med 1994;33:612-4
  • Charles PJ, Sweatman MC, Marckwick JR, et al. HLA-B40 a marker for susceptibility to lung disease in rheumatoid arthritis. Dis Markers 1991;9:97-101
  • Clarkson R, Bate AS, Grennan DM, et al. DQw7 and C4B null allele in rheumatoid arthritis and Feltys syndrome. Ann Rheum Dis 1990;49:976-9
  • Michalski JP, McCombs CC, Scopelatis E, et al. Alpha 1 antitrypsin phenotypes in pulmonary disease associated with rheumatoid arthritis and systemic sclerosis. Arthritis Rheum 1986;29:586-91
  • Alexiou I, Germenis A, Koutroumpas A, et al. Anti-cylcic citrullinated peptide (CCP) antibodies and extra articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol 2008;27(4):511-3
  • Inui N, Enomoto N, Suda T, et al. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem 2008;41(13):1074-7
  • Hamilton J, Kelly CA. What kills patients with rheumatoid arthritis? Rheumatology 2007;46;183-4
  • Coyne P, Hamilton J, Heycock C, et al. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol 2007;34:1832-7
  • Howes M, Tose J, White C, et al. Can baseline pulmonary function tests predict pulmonary toxicity in patients receiving methotrexate for rheumatoid arthritis. Intern Med 1999;7:51-4
  • Gaffo AL, Alarcon GS. Methotrexate is not associated with progression of interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008;168(17):1927-8
  • Saravanan V, Kelly CA. Drug related pulmonary problems in patients with rheumatoid arthritis. Rheumatology 2006;45(7):787-90
  • Kamata Y, Nara H, Kamimura T, et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 2004;43:1201-4
  • Hagiwara K, SatoT, Takagi-Kobayashi S, et al. Acute exacerbation of pre-existing interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 1997;34:1151-4
  • Ostor AJK, Crisp AJ, Somerville MF, Scott DGI. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004;1266-7
  • Collins K, Todd A, Rynne M, et al. Re-Adalimumab-associated pulmonary fibrosis. Rheumatology 2007;46(8):1379-80
  • Dixon W, Watson K, Lunt M, Hyrich K. Rheumatoid arthritis, interstitial lung disease, mortality and anti-TNF therapy: results from the BSR Biologics Register (BSRBR) [abstract 0014]. Ann Rheum Dis 2007;66(Suppl)
  • Silburn S, Bhatt S, Galarraga B, et al. TNF alpha blockade can exacerbate pulmonary fibrosis in rheumatoid arthritis patients taking methotrexate. Rheumatology 2008;47(2):ii19(no 59)
  • Benbow J, O'Callaghan A, Rynne M, et al. Lung disease in patients receiving anti-TNF therapy for rheumatoid arthritis. Rheumatology 2008;47(2):ii113(no 388)
  • Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with Etanercept: an exploratory, placebo-controlled trial [abstract no. 446] [Oral Communication]. Am J Respir Crit Care Med 2007;9 (Abs number 446)
  • Whitfield JC, Jones D, Ferrara JLM, et al. The impact of soluble tumor necrosis factor receptor: etanercept on the treatment of idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation. Blood 2008 [Epub]
  • Nochuico BR, Avila NA, Chow CK, Novero LJ. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008;168(2)159-66
  • Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248-54
  • Collard HR, Ryu JH, Douglas WW, et al. Combined corticosteroids and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004;125:2169-74
  • Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354(25):2655-66
  • Walter N, Collard HR, King JE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006;3:330-8
  • Van Laar JM, Stolk J, Tyndall A, et al. Scleroderma lung. Pathogenesis, evaluation and current therapy. Drugs 2007;67:985-96
  • Vassallo R, Thomas CF. Advances in treatment of rheumatic interstitial lung disease. Curr Opin Rheumatol 2004;16:186-91
  • Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353(21):2229-42
  • Hubbard R, Barker B, Fogarty A, Smith C. Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2007;30(Suppl 51):246s, 1574
  • Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:1475-82
  • Swigris J, Olson A, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006;130:30-3
  • Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008;133(2):455-60
  • Liossis SNC, Bounas A, Andonopoulos AP. Mycophenolate mofetil as firstline treatment improves clinically evident early scleroderma lung disease. Rheumatol (Oxf) 2006;45(8):1005-8
  • Zamora AC, Wolters PJ, Collard HR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008;102(1):150-5
  • Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic Drug. Arch Intern Med 2008;168(15):1718-9
  • Lim SW, Gillis D, Smith W, et al. Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports. Int Med J 2006;36:260-2
  • Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46(10):2673-7
  • Niewold T, Albert D, Scanzello C, et al. Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease. J Rheumatol 2006;33(6):1194-6
  • Ng KP, Leandro MJ, Edwards JC, et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006;65:942-5
  • Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005;52(10):3168-74
  • Binstadt BA, Caldas AMC, Turvey SE, et al. Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr 2003;143:598-604
  • Lambotte O, Kotb R, Maigne G, et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005;32:1369-70
  • Stasi R, Stipa E, Del Poeta G, et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology 2006 [Epub 2006 21 Apr]
  • Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Int Med 2005;257:540-8
  • Keogh KA, Wylam ME, Stone JH, et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52(1):262-8
  • Keogh KA, Ytterberg S, Fervenza FC, et al. Rituximab for refractory Wegener's Granulomatosis. Report of a prospective, open label pilot trial. Am J Respir Crit Care Med 2006;173:180-7
  • Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006;65:853-8
  • Koukoulaki M, Abeygunasekara SC, Smith KGC, et al. Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant 2005;20:213-6
  • Koukoulaki M, Smith K, Wayne D, et al. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 2006;65:557-59
  • Kaushik V, Reddy H, Bucknall R. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis 2006;65:1116-7
  • Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002;61:922-4
  • Popa C, Leandro MJ, Cambridge G, Edwards JCW. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 years. Rheumatology 2007;46:626-30
  • Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of anti-synthetase syndrome. Ann Rheum Dis 2006;65:974-5
  • Leon RJ, Gonsalvo A, Salas R, Hidalgo NC. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 2004;79(7):945-56
  • Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Haematol 2007;82:916-9
  • Jadon D, Chan A, McNally J. Life threatening leflunomide pneumonitis in a patient on rituximab. Rheumatology 2008;47(2):ii158 (no 549)
  • Teichmann L, Woenckhaus M, Vogel C, et al. Fatal pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology 2008;47(8):1256-7
  • Jung N, Owczarczyk K, Hellmann M, et al. Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatology 2008;47:932-3
  • Atkins SA, Turesson C, Myers JL, et al. Morphologic and quantitative assessment of CD-20 B cell infiltrates in rheumatoid arthritis associated non specific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 2006;54:635-41
  • Paniagua RT, Robinson WH. Imatinib in the treatment of rheumatic diseases. Nat Clin Pract Rheumatol 2007;3(4):190-1
  • Distler JHW, Distler O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology 2008;47:v10-1, doi:10.1093
  • Rosenbloom J, Jiminez SA. Molecular ablation of transforming growth factor beta signalling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis. Arthritis Rheum 2008;58(8):2219-24
  • Sabnani I, Zucker MJ, Rosenstein ED, et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology [Epub 2008 Sept 24]
  • Distler JH, Manger B, Schett G, et al. Treatment of pulmonary fibrosis for 20 weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis Rheum 2008;58(8):2538-42
  • Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006;2:(11):619-26
  • Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002;4(Suppl 3):S233-42
  • Sack U, Kinne R, Marx T, et al. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int 1993;13:45-51
  • Madhok R, Crilly A, Watson J, et al. Serum interleukin 6 levels in rheumatoid arthritis: correlation with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993;52:232-4
  • Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomised controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54(9):2817-29
  • Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97
  • Nanini C, Ryu JH, Matteson EL. Lung disease in rheumatoid arthritis. Curr Opin Rheumatol 2008;20(3):340-6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.